3 Stocks That Soared Stupendously This Week

The 4th of July brought plenty of fireworks – but the days leading up to the nation’s birthday brought other types of excitement. Here are three health-care stocks that soared and sizzled.

12

3

Shares of the biotech jumped 12% higher for the week.

Regeneron Pharmaceuticals (NASDAQ:REGN)

Source: Yahoo! Finance

• French drugmaker Sanofi (NYSE:SNY) announced on Tuesday that it was increasing its stake in Regeneron

• This move gives Sanofi a 22.5% stake in Regeneron – up from 20.5%

• Sanofi’s decision follows a recommendation last week by the European Committee for Medicinal Products, or CHMP, for approval of Eylea in treating visual impairment due to diabetic macular edema

• Regeneron and Sanofi are collaborating on eight human monoclonal antibodies

Why Regeneron shares were rejuvenated

Shares of the biopharmaceutical company shot up 16% higher this week.

TG Therapeutics (NASDAQ:TGTX)

Source: Yahoo! Finance

• TG Therapeutics benefited from positive comments from investment firm MLV & Co. on Wednesday

• MLV reiterated its “buy” rating and raised the price target for TG from $10 to $16 because of the biotech’s solid pipeline

• Shares of TG Therapeutics received a big boost last week after the company announced a global licensing deal with Ligand Pharmaceuticals (NASDAQ:LGND)

• Ligand exchanged licensing rights for its IRAK4 inhibitor for 125,000 shares of TG – with the deal adding more depth to TG’s pipeline

Why TG’s stock took off

Shares of the biopharmaceutical firm surged 32% this week.

Amicus Therapeutics (NASDAQ:FOLD)

Source: Yahoo! Finance

• Amicus gave an update on a clinical study of migalastat on Monday

• While top-line results won’t be released until third quarter, the final patient completed the 18-month treatment period with all but one of 32 patients opting to continue receiving the drug in the 12-month extension study

• The news generated excitement in the analyst community, with JP Morgan, Janny, and Leerink Partners upgrading Amicus and increasing price targets

Why Amicus shares received a friendly bump

• There’s plenty to like about all three stock’s prospects

• Amicus could have a bright future with migalastat, while Regeneron keeps on rocking with Eylea

• The nod for most room to run, though, goes to TG Therapeutics

• TG’s ublituximab and TGR-1202 could be winners, while the licensing deal with Ligand gives the company another path to success

• More positive clinical results could make TG an attractive acquisition target for bigger drugmakers

Best pick to keep soaring?

?

Cable’s going away. But do you know how to profit? There’s $2.2 trillion at stake. Find out which 3 companies stand ready to benefit -- and they’re not Netflix, Google, and Apple!